All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
VIENNA – On track to file for regulatory approval later this year in both the U.S. and Europe, Intercept Pharmaceuticals Inc. solidified its position as a research leader in the nonalcoholic steatohepatitis (NASH) with liver fibrosis field, presenting a broader dataset of its phase III trial of obeticholic acid (OCA, Ocaliva).